- Home
- CALC
CALC
CalciMedica Inc.
as 09-08-2025 4:00pm EST
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | LA JOLLA |
| Market Cap: | 48.1M | IPO Year: | N/A |
| Target Price: | $14.50 | AVG Volume (30 days): | 53.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.57 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.42 - $5.97 | Next Earning Date: | 08-12-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of CalciMedica Inc. (CALC)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Roberts Eric W | CALC | CHIEF BUSINESS OFFICER | Aug 29 '25 | Buy | $2.74 | 800 | $2,192.00 | 70,907 | |
| Roberts Eric W | CALC | CHIEF BUSINESS OFFICER | Aug 28 '25 | Buy | $2.86 | 9,200 | $26,339.60 | 70,907 | |
| Roberts Eric W | CALC | CHIEF BUSINESS OFFICER | Aug 21 '25 | Buy | $2.79 | 3,508 | $9,797.14 | 70,907 | |
| Roberts Eric W | CALC | CHIEF BUSINESS OFFICER | Aug 20 '25 | Buy | $2.72 | 2,000 | $5,440.00 | 70,907 | |
| Roberts Eric W | CALC | CHIEF BUSINESS OFFICER | Aug 19 '25 | Buy | $2.79 | 1,000 | $2,790.00 | 70,907 | |
| Hebbar Sudarshan | CALC | Chief Medical Officer | Aug 19 '25 | Buy | $2.82 | 9,563 | $26,961.92 | 61,539 | |
| Roberts Eric W | CALC | CHIEF BUSINESS OFFICER | Aug 15 '25 | Buy | $2.90 | 5,076 | $14,708.73 | 70,907 | |
| Hebbar Sudarshan | CALC | Chief Medical Officer | Aug 15 '25 | Buy | $2.79 | 4,392 | $12,266.86 | 61,539 | |
| Hebbar Sudarshan | CALC | Chief Medical Officer | Aug 14 '25 | Buy | $2.59 | 1,584 | $4,094.64 | 61,539 | |
| Roberts Eric W | CALC | CHIEF BUSINESS OFFICER | Jun 11 '25 | Buy | $1.85 | 5,000 | $9,250.00 | 70,907 |
Latest CalciMedica Inc. News
CALC Breaking Stock News: Dive into CALC Ticker-Specific Updates for Smart Investing
PR Newswire
2 months ago
CalciMedica to Participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference
PR Newswire
2 months ago
CalciMedica Announces Publication in the American Journal of Nephrology Discussing Design and Rationale of Phase 2 KOURAGE Trial of Auxora™ in AKI with Respiratory Failure
Simply Wall St.
3 months ago
CalciMedica Insiders Added US$1.05m Of Stock To Their Holdings
PR Newswire
3 months ago
CalciMedica Announces Upcoming Symposium at the 43rd Vicenza Course AKI-CRRT-EBPT and Critical Care Nephrology Meeting
PR Newswire
4 months ago
CalciMedica Reports First Quarter 2025 Financial Results and Provides Clinical & Corporate Updates
PR Newswire
5 months ago
CalciMedica Announces Presentations at Upcoming Medical Meetings
PR Newswire
5 months ago
CalciMedica to Participate in the Jones Healthcare and Technology Innovation Conference
PR Newswire
5 months ago
CalciMedica Reports 2024 Financial Results and Provides Clinical & Corporate Updates
Compare CALC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CALC CalciMedica Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.